Qube Research & Technologies (QRT)’s Sarepta Therapeutics SRPT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,598,472	Closed	-$27.3M	–	3932
2025 Q2	$27.3M	Buy	1,598,472 +1,566,564	+4,910%	+$66.8M	0.03%	717
2025 Q1	$2.04M	Buy	+31,908	New	+$3.36M	﹤0.01%	1952
2024 Q2	–	Sell	-11,869	Closed	-$1.54M	–	4674
2024 Q1	$1.54M	Buy	11,869 +10,650	+874%	+$1.3M	﹤0.01%	1894
2023 Q4	$118K	Buy	1,219 +946	+347%	+$90.7K	﹤0.01%	3046
2023 Q3	$33.1K	Buy	+273	New	+$30.9K	﹤0.01%	2991
2022 Q4	–	Sell	-12,728	Closed	-$1.41M	–	2966
2022 Q3	$1.41M	Buy	+12,728	New	+$1.28M	0.01%	1067
2021 Q2	–	Sell	-31,662	Closed	-$2.36M	–	2772
2021 Q1	$2.36M	Sell	31,662 -4,063	-11%	-$375K	0.04%	576
2020 Q4	$6.09M	Buy	+35,725	New	+$5.29M	0.09%	265
2020 Q3	–	Sell	-23,926	Closed	-$3.84M	–	2081
2020 Q2	$3.84M	Buy	+23,926	New	+$3.26M	0.06%	441

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Qube Research & Technologies (QRT)'s SRPT Position: Q3 2025 in Review

Qube Research & Technologies (QRT) sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 1,598,472 shares — an estimated $27.3M sold.

Qube Research & Technologies (QRT) first reported a position in SRPT in Q2 2020 and held it in 9 quarters. The position peaked at $27.3M in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Qube Research & Technologies (QRT) reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 1,598,472 Sarepta Therapeutics shares in Q3 2025, an estimated $27.3M.
Qube Research & Technologies (QRT) first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 9 quarters.
Qube Research & Technologies (QRT)'s Sarepta Therapeutics position peaked at $27.3M in Q2 2025.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2025, filed 14 Nov 2025.